Fatigue and sleep disturbances are two of the most common and distressing symptoms reported by cancer patients. Fatigue and sleep are also correlated with each other. While fatigue has been reported to be associated with some inflammatory markers, data about the relationship between cancer-related sleep disturbances and inflammatory markers are limited. This study examined the relationship between fatigue and sleep, measured both subjectively and objectively, and inflammatory markers in a sample of breast cancer patients before and during chemotherapy. Fifty-three women with newly diagnosed stage I-III breast cancer scheduled to receive at least four 3-week cycles of chemotherapy participated in this longitudinal study. Fatigue was assessed with the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), sleep quality was assessed with the Pittsburgh Sleep Quality Index (PSQI) and objective sleep was measured with actigraphy. Three inflammatory markers were examined: Interleukin-6 (IL-6), Interleukin-1 receptor antagonist (IL-1RA) and C-reactive protein (CRP). Data were collected before (baseline) and during cycle 1 and cycle 4 of chemotherapy. Compared to baseline, more fatigue was reported, levels of IL-6 increased and IL-1RA decreased during chemotherapy. Reports of sleep quality remained poor. Mixed model analyses examining changes from baseline to each treatment time point revealed overall positive relationships between changes in total MFSI-SF scores and IL-6, between changes in total PSQI scores and IL-6 and IL-1RA, and between total wake time at night and CRP (all p's < 0.05). These relationships suggest that cancer-related fatigue and sleep disturbances may share common underlying biochemical mechanisms.
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Introduction
Fatigue and sleep disturbances are two of the most common and distressing symptoms of patients with cancer. About 70-80% of cancer patients complain of fatigue (Hofman et al., 2007) and 30-75% of newly diagnosed or recently treated cancer patients report sleep problems (Ancoli-Israel et al., 2001; Berger et al., 2005) . Indeed, both cancer and cancer treatment-related fatigue are closely associated with both subjectively and objectively measured sleep problems (Ancoli-Israel et al., 2001; Liu et al., 2012; Roscoe et al., 2007) .
In addition to the close relationship with sleep disturbances, cancer-related fatigue (CRF) is also associated with multiple other factors, including anemia, fever, pain, weight loss, medication, infection, and depression (Bardwell and Ancoli-Israel, 2008; Kurzrock, 2001 ). Sleep disturbances in cancer patients are also associated with multiple factors, such as depression, anxiety, treatment (e.g., chemotherapy and radiation), cancer treatmentinduced hot flashes, pain, fatigue and changes of biological rhythms (Ancoli-Israel et al., 2001; Liu and Ancoli-Israel, 2008) . CRF and sleep disturbances are both prominent components of a group of ''sickness behaviors'' originally reported in cancer patients receiving systemic administration of cytokines, such as interferon-a (IFN-a), interleukin-2 (IL-2), and tumor necrosis factor-a (TNF-a), for the treatment of the cancer (Kelley et al., 2003; Lee et al., 2004) .
